Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Solaredge Technologies Inc (SEDG) vs Viatris Inc (VTRS) Price & Performance

Solaredge Technologies IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Solaredge Technologies Inc vs Viatris Inc — how do they compare? Solaredge Technologies Inc trades at $35.35 (market cap $2.24B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Viatris Inc is far larger — about 8.5× Solaredge Technologies Inc's market cap, and Viatris Inc pays a 2.89% dividend while Solaredge Technologies Inc pays none. Which is the better fit depends on your goals.

SEDGVTRS
Market Cap
$2.24B$19.09B
Sector
TechnologyHealth
52-Week High
$78.51$17.86
52-Week Low
$28.47$9.49
Enterprise Value
$2.10B$31.21B
Dividend Yield
2.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Solaredge Technologies Inc

SolarEdge Technologies (SEDG) trades at $36.43, up 6.52% with a bullish technical signal despite negative profitability metrics. The stock shows mixed earnings performance with recent beats but faces significant challenges including a -20.29% net income margin and negative ROE. Recent news highlights collaboration with Infineon for AI data center technology and positive analyst upgrades from UBS citing 40% upside potential.

The outlook remains challenging with persistent losses and high debt levels, though recent technical strength and AI infrastructure developments offer potential catalysts. Key risks include execution challenges, policy dependency, and competitive pressures in the solar sector. Analyst consensus is mixed with 23% buy ratings but a $36.13 price target slightly below current levels.

Viatris Inc

Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.

The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Solaredge Technologies Inc

SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.

Read more on SEDG

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS